Integris Medtech IPO
Integris Medtech IPO on BSE, NSE. Opens 27 Nov 2026 and closes 1 Dec 2026. Allotment 2 Dec 2026. Listing 4 Dec 2026.
Price Band
—
Bookbuilding IPO
Lot Size
—
Issue Size
—
Fresh: ₹600.00 Cr
Latest GMP
₹0
IPO Timeline & Milestones
All dates anchored to Indian Standard Time (IST)
Subscription Quota Allocation
SEBI Category Reservation Breakdown
10%
Retail Investors
Up to ₹2,00,000
75%
QIB Quota
Institutional FIs / MFs
15%
HNI / NII Quota
Above ₹2,00,000
Grey Market Premium (GMP)
At Par / Neutral₹0
Quote observed
Upper Price Band
—
Retail Lot Size
—
Min. Investment (1 Lot)
—
Est. Lot Value
—
Grey market quotes are unofficial, unregulated sentiment indicators and do not guarantee listing returns.
Historical GMP Trend
Chronological grey market premium movements
| Observation Date | GMP Premium | Daily Trend | Expected Listing | Recorded At |
|---|---|---|---|---|
| 22 Nov 2026 | ₹0 | 0 | — | 22 Nov 2026, 8:34 am |
| 21 Nov 2026 | ₹0 | 0 | — | 21 Nov 2026, 6:50 pm |
| 21 Nov 2026 | ₹0 | 0 | — | 21 Nov 2026, 5:43 am |
| 20 Nov 2026 | ₹0 | — | — | 20 Nov 2026, 5:12 pm |
Sector Benchmark · Pharmaceuticals & Healthcare
Historical Listing-Day Performance
Listing-day debut returns compared against issue price across healthcare peers.
Sector Avg. Gain
+16.7%
Across 6 sector peers
Median Debut
+19.4%
Typical listing return
Positive Debuts
6/6
100% listed above issue
Top Sector Debut
+31.4%
Emcure Pharmaceuticals
| Company | Cohort | Issue Price | Listing Price | Listing Gain |
|---|---|---|---|---|
Emcure Pharmaceuticals | 2024 · Mainboard | ₹1,008 | ₹1,325 | +31.4% |
Concord Biotech | 2023 · Mainboard | ₹741 | ₹900 | +21.5% |
Mankind Pharma | 2023 · Mainboard | ₹1,080 | ₹1,300 | +20.4% |
Sai Life Sciences | 2024 · Mainboard | ₹549 | ₹650 | +18.4% |
Akums Drugs & Pharma | 2024 · Mainboard | ₹679 | ₹725 | +6.8% |
| 2026 · Mainboard | ₹693 | ₹706 | +1.9% |
Combines 1 tracked listed Pharmaceuticals & Healthcare peer with historical NSE/BSE sector IPO debuts. Historical listing-day gains are shown for educational sector context only and do not guarantee future listing performance.
Integris Medtech IPO Financials
Restated Consolidated
| Period Ended | 30 Jun 2025 | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
|---|---|---|---|---|
| Assets | 4,019.62 | 3,641.34 | 2,989.20 | 2,553.87 |
| Total Income | 508.93 | 1,959.58 | 1,582.26 | 1,369.66 |
| Profit After Tax | 267.57 | 70.68 | -4.88 | -40.54 |
| EBITDA | 78.73 | 309.40 | 190.45 | 168.82 |
| NET Worth | 3,889.99 | 2,752.52 | 2,681.02 | 2,629.52 |
| Reserves and Surplus | 2,299.84 | 1,150.74 | 1,135.71 | 1,073.12 |
| Total Borrowing | 793.42 | 1,729.46 | 813.10 | 556.54 |
Amount in ₹ Crore
Financial Highlights
Key performance metrics from audited statements
Revenue
₹1,959.58 Cr
Profit After Tax (PAT)
₹70.68 Cr
Fresh Issue
₹600.00 Cr
Shareholding Structure
| Category | Pre IPO | Post IPO |
|---|---|---|
| Promoter and Promoter Group | 83.24% | — |
| Public | 16.76% | — |
| Total | 100% | — |
Company Promoters Evercure Holdings Pte.Ltd., Medicore Holdings Pte.Ltd., Gurmit Singh Chugh and Punita Sharma.
About Integris Medtech
Company overview and operations summary
Integris Medtech IPO Review
Company analysis, investment strengths and risk factors
Integris Medtech Ltd, incorporated in 2008, is a diversified global MedTech company operating across cardiovascular devices, clinical diagnostics, and scient…
Read full IPO reviewExplore Other Mainboard IPOs
Compare issue dates, price bands, and sentiment with other active public issues.